Atrium Therapeutics, Inc. Common Stock (RNA) Stock Price
Atrium Therapeutics, Inc. Common Stock Price
Over the last 14 years Atrium Therapeutics, Inc. Common Stock grew revenue by 3.6% annually, reaching 18.62 M USD. For Atrium Therapeutics, Inc. Common Stock, the net margin of -411.9% is up versus -1,258.5% a few years ago. The consensus 12-month price target for Atrium Therapeutics, Inc. Common Stock is 25.00 USD, about 288.8% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.
Atrium Therapeutics, Inc. Common Stock stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Atrium Therapeutics, Inc. Common Stock business model & stock analysis
Frequently asked questions about Atrium Therapeutics, Inc. Common Stock
Analysts currently set an average price target of 25.00 USD for the Atrium Therapeutics, Inc. Common Stock stock (median: 25.00 USD), implying +285.8 % versus the latest price. The consensus is based on 8 analyst ratings.
Atrium Therapeutics, Inc. Common Stock Analyst Price Targets 2026
8 analysts currently rate the Atrium Therapeutics, Inc. Common Stock stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Atrium Therapeutics, Inc. Common Stock to generate revenue of 35.02 M USD and earnings per share of -4.29 USD.
Atrium Therapeutics, Inc. Common Stock Analyst Price Targets 2026
Converted at the current exchange rate, the Atrium Therapeutics, Inc. Common Stock share trades at 5.86 EUR (6.43 USD).
The expected revenue of Atrium Therapeutics, Inc. Common Stock is 35.02 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Atrium Therapeutics, Inc. Common Stock is -73.48 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Atrium Therapeutics, Inc. Common Stock is currently -1.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Atrium Therapeutics, Inc. Common Stock stock.
The price-to-sales ratio (P/S) of Atrium Therapeutics, Inc. Common Stock is currently 3.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Atrium Therapeutics, Inc. Common Stock stock.
The Eulerpool Quality Score for Atrium Therapeutics, Inc. Common Stock is 5/10.
The ISIN of Atrium Therapeutics, Inc. Common Stock is US04965N1046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Atrium Therapeutics, Inc. Common Stock is RNA. The ticker symbol is used to trade Atrium Therapeutics, Inc. Common Stock shares on the stock exchange.
Atrium Therapeutics, Inc. Common Stock stock
Atrium Therapeutics, Inc. Common Stock Peer Group
All fundamentals and in-depth analysis of Atrium Therapeutics, Inc. Common Stock
Our stock analysis for Atrium Therapeutics, Inc. Common Stock stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atrium Therapeutics, Inc. Common Stock. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.